Literature DB >> 17849090

[Therapy of systemic sclerosis].

M Meurer1, P Rehberger.   

Abstract

The therapy of systemic sclerosis (SSc) remains a challenge for dermatology, rheumatology, internal medicine, and other disciplines. Organ involvement, above all kidney and lungs, is a key therapeutic issue. The current developments in organ-specific therapy are the main topic of the article. Finally, possibilities of disease-modifying drugs and value of HSCT are discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17849090     DOI： 10.1007/s00105-007-1404-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  59 in total

1.  Relaxin (Connetics/Celltech).

Authors:  R Jones
Journal:  IDrugs       Date:  2001-02

2.  Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

Authors:  H U Scherer; G-R Burmester; G Riemekasten
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

Review 3.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 4.  New therapeutic strategies in the management of systemic sclerosis.

Authors:  Yannick Allanore; Jèrôme Avouac; Julien Wipff; André Kahan
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

5.  Successful treatment of scleroderma with PUVA therapy.

Authors:  T Kanekura; S Fukumaru; S Matsushita; K Terasaki; S Mizoguchi; T Kanzaki
Journal:  J Dermatol       Date:  1996-07       Impact factor: 4.005

6.  Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis.

Authors:  J M van Laar; D Farge; A Tyndall
Journal:  Ann Rheum Dis       Date:  2005-10       Impact factor: 19.103

7.  Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study.

Authors:  Yannick Allanore; Christophe Meune; Olivier Vignaux; Simon Weber; Paul Legmann; Andre Kahan
Journal:  J Rheumatol       Date:  2006-10-15       Impact factor: 4.666

8.  [Gastrointestinal involvement in progressive systemic scleroderma].

Authors:  C Folwaczny; U Rothfuss; R L Riepl; P Lehnert; H Bloching; M Meurer; U Karbach
Journal:  Z Gastroenterol       Date:  1995-11       Impact factor: 2.000

Review 9.  [Iloprost therapy in systemic sclerosis].

Authors:  G Bali; E Aberer
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

10.  Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.

Authors:  K Dheda; U G Lalloo; B Cassim; G M Mody
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.